BG-75202
/ BeOne Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 11, 2026
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=86 | Recruiting | Sponsor: BeOne Medicines | Trial completion date: Jul 2036 ➔ Jan 2037 | Trial primary completion date: Apr 2029 ➔ Sep 2029
Trial completion date • Trial primary completion date • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
March 16, 2026
BG-75202-101: A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors
(clinicaltrialsregister.eu)
- P1 | N=15 | Not yet recruiting | Sponsor: BeOne Medicines I GmbH
New P1 trial • Oncology • Solid Tumor
December 19, 2025
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=86 | Recruiting | Sponsor: BeOne Medicines | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
October 30, 2025
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=86 | Not yet recruiting | Sponsor: BeOne Medicines
New P1 trial • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1